Journal article
Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma
Seminars in oncology, Vol.29(1S2), pp.93-97
02/2002
DOI: 10.1053/sonc.2002.30147
PMID: 28140098
Abstract
Synthetic oligodeoxynucleotides containing unmethylated cytosine-guanine dinucleotides (CpG ODN) are potent immunostimulatory agents that can activate various immune cell subsets. We have found that CpG ODN show a variety of effects that could be useful in enhancing the efficacy of antibody therapy of lymphoma. In a mouse model, CpG ODN alone had no effect on survival of animals inoculated with lymphoma. In contrast, CpG ODN plus monoclonal antibody (MAb) was more effective at inhibiting tumor growth than MAb alone or MAb plus control ODN. Cytosine-guanine ODN plus MAb cured mice with a large tumor burden that could not be cured with MAb therapy alone. We also evaluated the effects of CpG ODN on the phenotype of human malignant B cells. Cytosine-guanine ODN upregulated the expression of a number of antigens, including CD20. The upregulation of CD20 was most extensive in cells that had low baseline expression of this antigen. We conclude that CpG ODN enhances the efficacy of MAb in a murine lymphoma model, most likely by activating effector cells, and upregulates expression of CD20 on primary human malignant B cells. Given the effects of CpG ODN on both target antigen expression and effector-cell function, further evaluation of the combination of CpG ODN plus rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA) and CpG ODN plus other MAbs is warranted. Semin Oncol 29 (suppl 2):93-97. Copyright © 2002 by W.B. Saunders Company.
Details
- Title: Subtitle
- Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma
- Creators
- Thomas L Warren - HoldenGeorge J Weiner - Holden
- Resource Type
- Journal article
- Publication Details
- Seminars in oncology, Vol.29(1S2), pp.93-97
- DOI
- 10.1053/sonc.2002.30147
- PMID
- 28140098
- ISSN
- 0093-7754
- eISSN
- 1532-8708
- Language
- English
- Date published
- 02/2002
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984359809302771
Metrics
6 Record Views